Equities

Oxford Biomedica PLC

OXB:LSE

Oxford Biomedica PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)322.00
  • Today's Change2.00 / 0.63%
  • Shares traded-1.00
  • 1 Year change-21.94%
  • Beta1.4985
Data delayed at least 20 minutes, as of May 15 2024 16:35 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 15-May-24
Select bar for recommendation details.
Recommendations15-May-24
Buy1
Outperform4
Hold3
Underperform0
Sell0

Share price forecast

The 9 analysts offering 12 month price targets for Oxford BioMedica plc have a median target of 310.00, with a high estimate of 740.00 and a low estimate of 224.00. The median estimate represents a -3.13% decrease from the last price of 320.00.
High131.3%740.00
Med-3.1%310.00
Low-30.0%224.00

Earnings history & estimates

Oxford BioMedica plc reported annual 2023 losses of -60.28 per share on Apr 29, 2024.
Average growth rate+9.53%
More ▼

Revenue history & estimates

Oxford Biomedica plc had revenues for the full year 2023 of 89.54m. This was 36.04% below the prior year's results.
Average growth rate+15.43%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.